Brief: Titan Pharmaceuticals Inc And Musc Frd Enter Into Research And Option License Agreement
12/10/2021 13:16
Oct 12 (Reuters) - Titan Pharmaceuticals Inc TTNP.O :
* TITAN PHARMACEUTICALS AND MUSC FRD ENTER INTO RESEARCH AND
OPTION LICENSE AGREEMENT
* TITAN - TO EVALUATE AND POTENTIALLY LICENCE TETRAPEPTIDE
KAPPA-OPIOID AGONIST COMPOUNDS FOR USE IN COMBINATION WITH ITS
PRONEURA TECHNOLOGY PLATFORM
Source text for Eikon: ID:nPn9wQXJpa
Further company coverage: TTNP.O
Recent news on Titan Pharmaceuticals
See all newsBrief: Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock
Brief: Titan Pharmaceuticals- Appoints Brynner Chiam As Acting Principal Executive Officer & Acting Principal Financial Officer Of Co
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group
Titan Pharma falls as CEO announces resignation
Brief: Titan Pharmaceuticals Enters Into Merger Agreement With Ke Sdn. Bhd.